NIDA is broadening the scope for PAR 10-099, Collaborative Clinical Trials in Drug Abuse (Collaborative R01), to include non-pharmacological trials
Release Date: April 30, 2012
National Institute on Drug Abuse (NIDA)
The National Institute on Drug Abuse is issuing this notice to update the scope for PAR-10-099 “Collaborative Clinical Trials in Drug Abuse (Collaborative R01)" to include non-pharmacological trials.
This FOA seeks to support collaborative, multisite, clinical trials via combined R01 grant applications that all utilize a common clinical protocol with identical primary outcome(s). Previously, emphasis was placed on pharmacological and neuroimaging trials. This notice expands emphasis to include clinical trials focused on drug abuse prevention, treatment, services, or any clinical trials designed to answer specific questions about biomedical or behavioral interventions of drug abuse.
Please direct all inquiries to:
Jamie Biswas, Ph.D.
Chief, Medications Research Grants Branch
Division of Pharmacotherapies and Medical Consequences of Drug Abuse
National Institute on Drug Abuse
National Institutes of Health/DHHS
6001 Executive Boulevard, Room 4123, MSC 9551
Bethesda, MD 20892-9551
Rockville, MD 20852 (for express/courier service)
Telephone: (301) 443-8096
Fax: (301) 443-9649
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Office of Extramural
National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
Department of Health
and Human Services (HHS)
NIH . . . Turning Discovery Into Health
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.